🟡 Preliminary Evidence
The U.S. Food and Drug Administration (FDA) has announced a recall of Hologic’s BioZorb 3D bioabsorbable markers, implantable devices used to mark soft tissue during surgical and diagnostic procedures. The recall follows reports of patient complications associated with the devices, prompting Hologic to remove the product from the market.
Key takeaways
- Hologic is voluntarily recalling all BioZorb 3D bioabsorbable markers due to documented patient complications
- The markers are implantable devices designed to mark soft tissue for surgical and diagnostic procedures
- Healthcare providers should cease use and contact affected patients; the FDA recommends clinical assessment for any adverse events
- This marks a significant safety action by the FDA’s Medical Device Approval and Safety Division
Device Purpose and Clinical Use
BioZorb 3D markers are bioabsorbable implants intended to mark specific soft tissue locations during surgical planning, intraoperative guidance, and post-operative imaging assessments, according to FDA device classification documentation. The markers are placed percutaneously and are designed to be absorbed over time, allowing surgeons to identify and target lesions or regions of interest with precision.
These devices are commonly used in breast surgery, soft tissue intervention, and other minimally invasive procedures where anatomical localization is critical for clinical decision-making.
Reported Complications and Safety Concerns
According to the FDA’s official recall notice, patient complications associated with BioZorb 3D markers have prompted this urgent safety action. While the specific adverse event profile is detailed in the regulatory filing, the complications are significant enough to warrant removal of all devices currently in circulation.
Healthcare facilities that have implanted these markers are instructed to contact affected patients and assess them clinically for any signs of device-related injury or inflammation. The FDA’s Medical Device Safety Office has classified this as a Class II recall, indicating potential for serious adverse health consequences.
Hologic voluntarily removes BioZorb 3D bioabsorbable markers from the market following documented patient complications, with all healthcare facilities directed to cease use and notify affected patients.
— U.S. Food and Drug Administration, Medical Device Recall Notice (2024)
Clinical and Regulatory Implications
This recall represents a critical patient safety intervention requiring immediate institutional response. Surgical teams must identify all patients who received BioZorb 3D markers and conduct clinical assessments to determine whether adverse events have occurred, according to FDA post-market surveillance guidance. Healthcare providers should document any complications and report them to both Hologic and the FDA MedWatch program.
For patients with implanted markers, clinical follow-up should include physical examination, imaging review, and symptom assessment. In cases where complications are identified, additional intervention may be necessary. The recall underscores the importance of robust post-market surveillance systems in detecting device-related safety signals early. See also: Quality & Safety coverage on news.gmj.ge for related regulatory updates.
What this means
Frequently asked questions
Do I need to have my BioZorb 3D marker surgically removed?
The decision to remove a marker depends on clinical assessment by your surgeon and whether you have experienced complications. Because the markers are designed to be bioabsorbable, your surgeon will evaluate whether removal, observation, or imaging follow-up is most appropriate for your individual case.
What symptoms should I watch for if I have a BioZorb 3D marker?
Symptoms that warrant immediate contact with your surgeon include increasing pain at the implant site, swelling, redness, drainage, fever, or imaging findings of marker migration or inflammation. Early reporting of symptoms is important for timely clinical management.
How can I find out if I received a BioZorb 3D marker?
Contact the surgical facility where your procedure was performed and request a copy of your operative report and implant documentation. Your surgeon’s office will have records indicating which specific devices were used during your procedure.
Healthcare systems and individual providers are urged to follow FDA guidance on device recalls and patient notification to ensure comprehensive management of affected patients. As post-market surveillance continues, additional information about the complication profile may be released, and clinicians should monitor FDA MedWatch updates and professional society communications for emerging data.
Source: FDA Medical Device Recall Notice: BioZorb 3D Bioabsorbable Markers
Was this article helpful?
Related Coverage
